心流公司 HTFL

John C.M. Farquhar has served as our Chief Executive Officer and as a member of our Board since March 2022 and as our President since January 2022, and he served as our Chief Operating Officer from July 2021 to March 2022. Prior to joining the Company, from March 2008 to July 2021, Mr. Farquhar held numerous positions of increasing responsibility across the cardiovascular and diabetes portfolios of Medtronic Public Limited Company (Medtronic), a global medical technology company, most recently serving as President and General Manager from June 2018 until July 2021. Prior to that, Mr. Farquhar served as a Marketing Manager at General Mills, Inc., a multinational manufacturer and marketer of branded processed consumer foods, from January 2004 until March 2008. He received a B.A. in Psychology and History from Duke University and an M.B.A. from Northwestern University's Kellogg School of Management.

Vikram Verghese has served as our Chief Financial Officer since June 2023. He joined the Company in November 2021 as Senior Vice President of Upstream Marketing, Business Development, and Strategy. Prior to that, Mr. Verghese held various positions at Medtronic from 2008 until 2021 in various leadership roles spanning global marketing, regulatory and clinical affairs and business development. After completing his undergraduate degree in Electrical and Electronic Engineering in India, Mr. Verghese received an M.S. in Biomedical Engineering from the University of Southern California and an M.B.A. from University of Pennsylvania's The Wharton School. He is also a CFA charter holder.

Campbell D.K. Rogers, M.D. has served as our Chief Medical Officer since March 2012. Prior to joining the Company, Dr. Rogers was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation (Cordis), a medical device company that was formerly part of the Johnson & Johnson family of companies, from July 2006 until February 2012, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, Dr. Rogers was an Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology from July 1994 until July 2006 and a director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women's Hospital in Massachusetts from October 2000 until June 2006 where he was responsible for clinical care, education and research. Dr. Rogers served as a Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous publications in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the National Institute of Health and American Heart Association. He received an A.B. in English from Harvard College and an M.D. from Harvard Medical School.

Jeffrey C. Lightcap has served as a member of our Board since December 2011. Since 2007, Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, L.P. (HealthCor Partners), a venture capital investment manager focused on late-stage venture and early commercial stage healthcare companies in the diagnostic, therapeutic and medtech sectors. Since 2019, Mr. Lightcap has also served as Senior Managing Director at Healthcare Venture Partners, LLC, a venture capital investment manager focused on healthcare companies. From 1997 until 2006, Mr. Lightcap served as Senior Managing Director at JLL Partners, LLC, (JLL Partners) a leading middle-market private equity firm. Prior to JLL Partners, from 1993 until 1997, Mr. Lightcap served as a Managing Director in the mergers and acquisitions group at Merrill Lynch, Pierce, Fenner & Smith Incorporated (Merrill Lynch), a global financial services company. Prior to joining Merrill Lynch, Mr. Lightcap was Senior Vice President in the mergers and acquisitions group at Kidder, Peabody & Co. Incorporated, a brokerage company, and at Salomon Brothers Inc., a global financial institution. Mr. Lightcap currently serves on the board of directors of CareView Communications, Inc. (OTC: CRVW), RTI Surgical, Inc. and KellBenx Inc. Mr. Lightcap also previously served on the board of directors of a number of HealthCor Partners' portfolio of private companies, including AccessClosure, Inc., Sadra Medical, Inc., Practice Partners in Healthcare, Inc. and Paradigm Spine, LLC. Mr. Lightcap received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook and an M.B.A. from the University of Chicago.

William C. Weldon has served as Chair of our Board from June 2017 to May 2019 and since 2020 and also as a member of our Board since September 2014. Mr. Weldon is the former Chairman of the board and Chief Executive Officer of Johnson & Johnson (Nasdaq: JNJ), a global developer and manufacturer of healthcare products, having served in those positions from 2002 until his retirement in 2012. Mr. Weldon previously served in a variety of senior executive positions during his 41-year career with Johnson & Johnson until his appointment as Chairman of the board and Chief Executive Officer. Mr. Weldon previously served as a director of CVS Health Corporation (NYSE: CVS) until his retirement from that board in May 2023, Exxon Mobil Corporation (NYSE: XOM) until his retirement from that board in May 2021, JPMorgan Chase & Co. (NYSE: JPM) until his retirement from that board in May 2019, and The Chubb Corporation until its acquisition by ACE Limited in January 2016. Mr. Weldon has served on the board of Fairfax Financial Holdings Limited (TSX:FFH) since 2020, where he serves as chair of the governance and nominating committee. He is a member of various not-for-profit organizations and is also a member of the Board of Trustees for Quinnipiac University. Mr. Weldon received his B.A. in Biology from Quinnipiac University.

Timothy C. Barabe has served as a member of our Board since January 2022. Mr. Barabe served as the chief financial officer and executive vice president at Affymetrix, Inc. (acquired by Thermo Fisher Scientific Inc.), a provider of life science productions and molecular diagnostic products, from 2010 until his retirement in June 2013. Previously, Mr. Barabe served as senior vice president and chief financial officer of Human Genome Sciences, Inc., a biopharmaceutical company, from July 2006 until March 2010. From 2004 until 2006, he served as chief financial officer of Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, and with Novartis AG, a pharmaceutical company, from 1982 until August 2004 in a succession of senior executive positions in finance and general management, most recently as the chief financial officer of Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis AG. Prior to that, Mr. Barabe served as the president of the Specialty Lens Business Franchise and group vice president and chief financial officer of CIBA Vision Corporation, a contact lenses and lens care product manufacturer until 2003. Mr. Barabe has served on the board of directors of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) since 2016 and previously served on the board of directors of Veeva Systems Inc. (NYSE: VEEV) from September 2015 until June 2021, ArQule, Inc., from 2001 until January 2020, and Opexa Therapeutics, Inc. from 2014 until 2017. Mr. Barabe also currently serves on the board of directors of Vigilant Biosciences, Inc., a private company. Mr. Barabe received a B.B.A. in Finance from University of Massachusetts and an M.B.A. from the University of Chicago.

Julie A. Cullivan has served as a member of our Board since November 2020. She most recently served as the chief technology and people officer at Forescout Technologies, Inc. (Forescout), a network security software company, from June 2017 until January 2021. Prior to joining Forescout, Ms. Cullivan served as the executive vice president, business operations and chief information officer of FireEye, Inc., an enterprise cybersecurity company, from January 2013 until May 2017, and as a senior vice president at McAfee Corp., a global computer security software company, from April 2008 until October 2011. Additionally, Ms. Cullivan held executive roles at Autodesk, Inc., EMC Corporation, and Oracle Corporation. Ms. Cullivan has served on the board of directors of Axon Enterprises, Inc. (NASDAQ:AXON) since 2017, where she serves as member of the nominating and governance committee and of the enterprise risk and compliance committee, Cobalt Labs, Inc. since 2022, and OPSWAT, Inc. since 2021 and previously served on the boards of Astra Space, Inc. (NASDAQ: ASTR), Judy Security (a/k/a AaDya Security Inc.), and SADA Systems LLC. Ms. Cullivan received a B.S. in Finance from Santa Clara University.

On March 9, 2023, the Board of Directors of Silk Road Medical, Inc. appointed Mhairi Jones as Chief Accounting Officer and Vice President, Finance, effective immediately. Prior to this appointment, Ms. Jones served as the Company's Vice President, Finance and Accounting, a position she had held since February 2018. Prior to joining the Company, Ms. Jones served as Vice President of Finance of Avinger, Inc., a public traded company engaged in the treatment of peripheral arterial disease, from December 2014 to February 2018. Prior to Avinger, she served as Vice President, Finance and Administration of C8 MediSensors, Inc., a privately held noninvasive glucose monitoring company, from April 2011 to July 2013. Prior to that position, Ms. Jones served as Vice President, Finance and Administration of Xoft, Inc., a privately held oncology company that was acquired by iCAD in 2011. Before Xoft, she served as Corporate Controller of Kyphon Inc., which was acquired by Medtronic Inc. in 2007. Prior to Kyphon, she served as Senior Manager in the audit and assurance practice with PricewaterhouseCoopers LLP. Ms. Jones is a licensed Certified Public Accountant in the State of California. She earned her B.S. degree in accounting from Santa Clara University.